Towards a novel disruptive therapy in autoimmune disease
We are thrilled to announce that Inhibitec has been selected as a recipient of the NEOTEC 2021 grant provided by CDTI (Center for Industrial Technological Development) with the support of the Ministerio de Ciencia e Innovación. This prestigious grant is designed to impulse new entrepreneurial projects that leverage technology or knowledge developed from research activities, with a business strategy focused on technology development.
Our project, “Nuevas Terapias para Enfermedades Autoinmunes Basada en el Bloqueo de BAMBI” (SNEO-20211187), running from 01/01/2022 to 31/12/2023, aims to introduce a novel treatment for patients with Psoriasis (PsO), Psoriatic Arthritis (PsA), and Systemic Lupus Erythematosus (SLE). This treatment is based on an innovative anti-BAMBI monoclonal antibody (mAb). The project’s objectives will help advance our therapy toward clinical application through the following key milestones:
- Designing and selecting a humanized anti-BAMBI mAb suitable for patient treatment.
- Validating its therapeutic efficacy using preclinical models of PsO, PsA, and SLE.
- Demonstrating improvements over current treatments through comparative studies.
- Completing preclinical toxicity analyses prior to human administration.
With an initial budget approved of : 378.024 €, these objectives align with the goals of the NEOTEC program.
This project will be funded through the Mechanism for Recovery and Resilience and the “Next Generation EU” funds. As recipients, we are committed to fulfilling all obligations outlined in Regulation (EU) 2021/241 of the European Parliament and of the Council of February 12, 2021, establishing the Mechanism for Recovery and Resilience, as well as other relevant EU or national regulations leading this financing.
We extend our gratitude to CDTI for their support, and we are excited to embark on this journey of innovation and technological advancement in our industry.
